A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients

Chinese Medical Journal

Volumn 124, Issue 14, 2011, Pages 2132-2135

  Zhou, Zhong Guo ^a,b   Wu, Xiao Jun ^b   Li, Li Ren ^b   Peng, Zhi Heng ^b   Ding, Pei Rong ^b   Wang, Ruo Jing ^b   Pan, Zhi Zhong ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Colorectal cancer; Prognosis; Stage II; Stage III

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINIC ACID; GELATINASE A; OXALIPLATIN; VASCULOTROPIN;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ASSESSMENT; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RADICAL RESECTION; RECTUM CARCINOMA; REVIEW; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79960682149     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.14.010     Document Type: Review

References (18)

1. Chen CQ, Fang LK, Cai SR, Ma JP, Yang GX, Yang W, et al. Effects of diabetes mellitus on prognosis of the patients with colorectal cancer undergoing resection: a cohort study with 945 patients. Chin Med J 2010; 123: 3084-3088.
2. Chen WQ, Zhang SW, Zou XN, Zhao P. Cancer incidence and mortality in China, 2006. Chin J Ca Res 2011; 23: 3-9.
3. Wang N, Zhu WX, Xing XM, Yang L, Li PP, You WC. Time trends of cancer incidence in urban Beijing, 1998-2007. Chin J Ca Res 2011; 23: 15-20.
4. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552.
5. Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst 2002; 94: 1837-1846.
6. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425.
7. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006; 101: 1872-1879.
8. Takahari D, Yamada Y, Okita NT, Honda T, Hirashima Y, Matsubara J, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. J Oncology 2009; 76: 42-48.
9. Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. J Mol Cancer Ther 2009; 8: 821-833.
10. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855.
11. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. J Gastroenterol 2009; 136: 1669-1679.
12. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. J Cancer Epidemiol Biomarkers Prev 2009; 18: 1888-1893.
13. Oshima T, Kunisaki C, Yoshihara K, Yamada R, Yamamoto N, Sato T, et al. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol Rep 2008; 19: 1285-1291.
14. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003; 200: 183-194.
15. Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD, et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. J Ann Surg Oncol 2003; 10: 722-733.
16. Mysliwiec P, Pawlak K, Kuklinski A, Kedra B. Combined perioperative plasma endoglin and VEGF-α assessment in colorectal cancer patients. J Folia Histochem Cytobiol 2009; 47: 231-236.
17. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93: 583-596.
18. Zhou ZG, Pan ZZ, Wan DS, Li LR, Wu XJ, Ding PR, et al. Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy. Cancer (Chin) 2009; 28: 908-912.